Ami Kabadi

Ami Kabadi is a seasoned professional in the field of biomedical engineering and gene editing, currently serving as Senior Director of Discovery Research and Technology Development at Sarepta Therapeutics since May 2020, with previous roles as Director and Associate Director in Gene Editing Research and Development. Prior experience includes serving as a Founding Scientist at Element Genomics from January 2017 to May 2020, where the focus was on CRISPR/Cas9-based high-throughput screening and the company was later acquired by UCB Pharma. From August 2015 to January 2017, Ami worked as a Scientist at CRISPR Therapeutics, leading initiatives in gene-editing strategies aimed at treating Duchenne Muscular Dystrophy. Academic foundations were built at Duke University, culminating in a PhD in Biomedical Engineering, alongside earlier roles as a Graduate Teaching Assistant and intern positions at Flexcell International Corporation and Syngenta.